Effects of Psilocybin in Major Depressive Disorder

Brief Summary

The proposed pilot study will assess whether people with major depressive disorder experience psychological and behavioral benefits and/or harms from psilocybin. This study will investigate acute and persisting effects of psilocybin on depressive symptoms and other moods, attitudes, and behaviors. The primary hypothesis is that psilocybin will lead to rapid and sustained antidepressant response, as measured with standard depression rating scales.

Intervention / Treatment

  • Drug: Psilocybin

Condition or Disease

  • Major Depressive Disorder

Phase

Study Design

Study type: Interventional
Status: Completed
Study results: Has Results
Age: 21 Years to 75 Years   (Adult, Older Adult)
Enrollment: 27 ()
Funded by: Other

Masking

Clinical Trial Dates

Start date: Aug 10, 2017
Primary Completion: Dec 02, 2020
Completion Date: Dec 02, 2020
Study First Posted: Jun 08, 2017
Results First Posted: Dec 15, 2021
Last Updated: Dec 15, 2021

Sponsors / Collaborators

Lead Sponsor: N/A
Responsible Party: N/A

Eligibility Criteria

Sex: All
Minimum Age: 21
Maximum Age: 75

More Details

NCT Number: NCT03181529
Other IDs: IRB00101821
Study URL: https://ClinicalTrials.gov/show/NCT03181529
Last updated: Jun 16, 2022